Vivo Capital’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.22M Hold
275,000
– – 0.46% 42
2026
Q2
$5.08M Buy
+275,000
New +$4.35M 0.46% 38

Other funds holding AVTX

Vivo Capital's AVTX Position: Q3 2026 in Review

Vivo Capital held its Avalo Therapeutics (AVTX) position steady in Q3 2026 at 275,000 shares worth $4.22M. The position accounts for 0.46% of the portfolio, ranked #42.

Vivo Capital first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $5.08M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Vivo Capital held 275,000 shares of Avalo Therapeutics worth $4.22M as of Q3 2026.
  • Vivo Capital left its Avalo Therapeutics share count unchanged in Q3 2026.
  • Avalo Therapeutics made up 0.46% of Vivo Capital's portfolio in Q3 2026, its #42 holding.
  • Vivo Capital first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Vivo Capital's Avalo Therapeutics position peaked at $5.08M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.